Menu
Search
|

Menu

Close
X

Revance Therapeutics Inc RVNC.OQ (NASDAQ Stock Exchange Global Market)

20.99 USD
+0.00 (+0.00%)
As of Nov 16
chart
Previous Close 20.99
Open 21.00
Volume 134,671
3m Avg Volume 66,143
Today’s High 21.54
Today’s Low 20.54
52 Week High 37.45
52 Week Low 20.54
Shares Outstanding (mil) 36.99
Market Capitalization (mil) 802.63
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.90 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY18
3
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-2.823
FY17
-3.996
FY16
-3.165
FY15
-3.008
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.34
Price to Sales (TTM)
vs sector
244.85
20.58
Price to Book (MRQ)
vs sector
4.41
4.23
Price to Cash Flow (TTM)
vs sector
--
21.19
Total Debt to Equity (MRQ)
vs sector
0.00
13.84
LT Debt to Equity (MRQ)
vs sector
0.00
9.93
Return on Investment (TTM)
vs sector
-79.01
13.58
Return on Equity (TTM)
vs sector
-85.06
15.11

EXECUTIVE LEADERSHIP

Angus Russell
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
L. Daniel Browne
Co-Founder, President, Chief Executive Officer, Director, Since
Salary: $525,300.00
Bonus: $466,038.00
Tobin Schilke
Chief Financial Officer and Principal Financial Officer, Since 2018
Salary: --
Bonus: --
Abhay Joshi
Chief Operating Officer, Since 2015
Salary: $453,200.00
Bonus: $344,728.00
Caryn McDowell
Senior Vice President, General Counsel, and Corporate Secretary, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

7555 Gateway Blvd
NEWARK   CA   94560-1152

Phone: +1510.7423400

Revance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. It is engaged in the clinical development for RT002 injectable. RT002 injectable utilizes botulinum toxin-peptide complex in a saline-based formulation. In RT002 injectable, the peptide interacts with both extracellular structures and cell surface receptors in the targeted muscle. This interaction restricts the toxin molecule to the target site and reduces unwanted spread to other neighboring muscles. It is focusing on developing RT002 for the treatment of glabellar lines, cervical dystonia and plantar fasciitis.

SPONSORED STORIES